Pancreatic Cancer Research

ResearcherBrown UniversityActive in the last 2 years

Jack R. Wands

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1731-624X; OpenAlex author ID A5043258226. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 3 papers

Papers 8

  1. Corrigendum to "Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma" [Cancer Lett. 449 (2019) … Last author DOI 10.1016/j.canlet.2025.218118↗
  2. Corrigendum to "Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis" [Cancer Lett. 481 (2020) 63-75]. Co-author DOI 10.1016/j.canlet.2025.218119↗
  3. Corrigendum to "LRH1 promotes pancreatic cancer metastasis" [Cancer Lett. (2014) 24 350 (1-2) 15-24]. Co-author DOI 10.1016/j.canlet.2026.218518↗
  4. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Co-author DOI 10.1016/j.canlet.2020.02.039↗
  5. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2019.02.006↗
  6. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Co-author DOI 10.1186/s13045-019-0837-z↗
  7. LRH1 as a driving factor in pancreatic cancer growth. Co-author DOI 10.1016/j.canlet.2013.11.014↗
  8. LRH1 promotes pancreatic cancer metastasis. Co-author DOI 10.1016/j.canlet.2014.04.017↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoqun Dong · 8 shared papers, 2014–2026 · strength 1.10
  2. Qiushi Lin · 6 shared papers, 2014–2026 · strength 0.74
  3. Xuewei Bai · 5 shared papers, 2019–2026 · strength 0.74
  4. Katsuya Nagaoka · 5 shared papers, 2019–2026 · strength 0.74
  5. Kosuke Ogawa · 5 shared papers, 2019–2026 · strength 0.74
  6. Lianxin Liu · 3 shared papers, 2019–2026 · strength 0.38
  7. Rui Kong · 3 shared papers, 2019–2026 · strength 0.38
  8. Le Li · 3 shared papers, 2019–2026 · strength 0.38
  9. Howard P. Safran · 3 shared papers, 2019–2026 · strength 0.38
  10. Min Li · 2 shared papers, 2019–2026 · strength 0.30
  11. Yongwei Wang · 1 shared paper, 2026 · strength 0.22
  12. Yongwei Wang · 2 shared papers, 2019–2020 · strength 0.16
  13. Bei Sun · 1 shared paper, 2020 · strength 0.08
  14. Min Li · 1 shared paper, 2020 · strength 0.08
  15. Shaofan Weng · 2 shared papers, 2014 · strength 0.08
  16. Bei Sun · 1 shared paper, 2019 · strength 0.07
  17. Yumin Li · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.